Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN057 in hemophilia A or B without inhibitors
NCT06569108Phase 3Active, not recruiting
- Sponsor
- Alphamab Oncology
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Started Apr 2024; status: active, not recruiting.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT06569108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569108.